Cassava Sciences Inc. [NASDAQ: SAVA] gained 21.83% on the last trading session, reaching $15.68 price per share at the time. The company report on January 4, 2021 that Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer.
Dr. Kupiec will leverage three decades of drug development experience at Pfizer, Sanofi and Ciba-Geigy to lead the Company’s Phase 3 development of simufilam for Alzheimer’s disease.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Cassava Sciences, Inc. (Nasdaq: SAVA) a clinical-stage biotechnology company focused on Alzheimer’s disease, announced the appointment of James Kupiec, MD, to the newly created position of Chief Clinical Development Officer. Dr. Kupiec will lead the Phase 3 clinical development strategy for simufilam, Cassava Sciences’ investigational drug for the treatment of dementia in Alzheimer’s disease. Dr. Kupiec will also serve as a member of the executive management team, reporting to the President & CEO.
Cassava Sciences Inc. represents 24.97 million in outstanding shares, while the company has a total market value of $514.30 million with the latest information. SAVA stock price has been found in the range of $13.22 to $15.7998.
If compared to the average trading volume of 3.30M shares, SAVA reached a trading volume of 4240357 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Cassava Sciences Inc. [SAVA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SAVA shares is $19.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SAVA stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for Cassava Sciences Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on October 23, 2020. The new note on the price target was released on September 23, 2020, representing the official price target for Cassava Sciences Inc. stock.
The Average True Range (ATR) for Cassava Sciences Inc. is set at 1.26 The Price to Book ratio for the last quarter was 16.33, with the Price to Cash per share for the same quarter was set at 0.73.
Trading performance analysis for SAVA stock
Cassava Sciences Inc. [SAVA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 48.34. With this latest performance, SAVA shares gained by 107.13% in over the last four-week period, additionally plugging by 344.19% over the last 6 months – not to mention a rise of 118.54% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SAVA stock in for the last two-week period is set at 78.74, with the RSI for the last a single of trading hit 82.65, and the three-weeks RSI is set at 74.72 for Cassava Sciences Inc. [SAVA]. The present Moving Average for the last 50 days of trading for this stock 8.57, while it was recorded at 13.17 for the last single week of trading, and 6.36 for the last 200 days.
Cassava Sciences Inc. [SAVA]: A deeper dive into fundamental analysis
Return on Total Capital for SAVA is now -46.34, given the latest momentum, and Return on Invested Capital for the company is -22.20. Return on Equity for this stock declined to -22.20, with Return on Assets sitting at -21.23. When it comes to the capital structure of this company, Cassava Sciences Inc. [SAVA] has a Total Debt to Total Equity ratio set at 0.41. Additionally, SAVA Total Debt to Total Capital is recorded at 0.41, with Total Debt to Total Assets ending up at 0.38.
Reflecting on the efficiency of the workforce at the company, Cassava Sciences Inc. [SAVA] managed to generate an average of -$514,556 per employee.Cassava Sciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 21.50 and a Current Ratio set at 21.50.
Cassava Sciences Inc. [SAVA]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Cassava Sciences Inc. posted -0.04/share EPS, while the average EPS was predicted by analysts to be reported at -0.13/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 69.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SAVA.
An analysis of insider ownership at Cassava Sciences Inc. [SAVA]
There are presently around $108 million, or 26.80% of SAVA stock, in the hands of institutional investors. The top three institutional holders of SAVA stocks are: BLACKROCK INC. with ownership of 1,445,297, which is approximately -1.518% of the company’s market cap and around 5.80% of the total institutional ownership; VANGUARD GROUP INC, holding 1,273,401 shares of the stock with an approximate value of $19.97 million in SAVA stocks shares; and BLEICHROEDER LP, currently with $10.73 million in SAVA stock with ownership of nearly -34.84% of the company’s market capitalization.
Positions in Cassava Sciences Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 43 institutional holders increased their position in Cassava Sciences Inc. [NASDAQ:SAVA] by around 1,610,420 shares. Additionally, 20 investors decreased positions by around 869,439 shares, while 11 investors held positions by with 4,426,767 shares. The mentioned changes placed institutional holdings at 6,906,626 shares, according to the latest SEC report filing. SAVA stock had 22 new institutional investments in for a total of 1,052,466 shares, while 6 institutional investors sold positions of 94,147 shares during the same period.